GW,
>>will someone leak the news out, my experience has been someone always knows before we do.<<
IMO, what generally is known before data release is negative (or positive) anecdotal remarks from trial clinicians or from knowledgeable experts, as well as some sort of general problem with all the data (for instance versus historical data). Once the data is unblinded and analyzed the company, IMO, is required to release any material, adverse information in a timely manner (this is the basis behind my comment about unblinding on a Friday, the market doesn't reopen until Monday).
Since we haven't heard any news of an anecdotal nature, I suspect all that we might hear rumors of coming out of the adjuidication panel meeting would be if the average infection rate across the blinded data (in other words for ALL subjects, drug and placebo) was much higher than historical rates or very much lower. Additionally, I suppose site irregularities or unusual side effects could leak out of the adjudication process.
All of this is just conjecture, of course. We all know the results are going to be spectacularly positive, right? <g>
biowa |
